September 11, 2018 / 6:37 AM / a year ago

Vectura reviewing drug stockpiles as no-deal Brexit looms

Sept 11 (Reuters) - Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its plan for a “no-deal” Brexit, the British drugmaker said on Tuesday, and warned of a potential disruption to supply chains and higher costs.

The risk from Brexit uncertainty has increased in the first half of 2018 due to a higher probability of the UK exiting the European Union without a deal, Vectura said. (Reporting by Shashwat Awasthi in Bengaluru; Editing by Amrutha Gayathri)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below